Outlook Therapeutics, Inc.

NasdaqCM OTLK

Outlook Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 59.35 M

Outlook Therapeutics, Inc. Total Non-Current Liabilities is USD 59.35 M for the quarter ending September 30, 2024, a 954,168.13% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Outlook Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 6.22 K, a -89.87% change year over year.
Outlook Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 61.41 K, a -99.46% change year over year.
Outlook Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 11.45 M, a 1,025.53% change year over year.
Outlook Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2020 was USD 1.02 M, a -86.64% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqCM: OTLK

Outlook Therapeutics, Inc.

CEO	Mr. Lawrence A. Kenyon CPA
IPO Date	June 14, 2016
Location	United States
Headquarters	Building F
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Key trends

Past 5 years